Status:
RECRUITING
Colon Cancer Liquid Biopsy Investigation of Methylation-based Biomarkers Evaluation Using Delta-HLD (CLIMBED)
Lead Sponsor:
Epiliquid Holding, Inc
Conditions:
Colorectal Cancer (CRC)
Eligibility:
All Genders
45-75 years
Brief Summary
CLIMBED (Colon cancer Liquid biopsy Investigation of Methylation-based Biomarkers Evaluation using Delta-HLD) is a non-randomized, observational, cross-sectional clinical validation study designed to ...
Detailed Description
Colorectal cancer (CRC) is one of the most common cancers worldwide and among the leading causes of cancer-related mortality. Early detection substantially improves survival; however, adherence to exi...
Eligibility Criteria
Inclusion
- Men and women aged 45-75 years
- Indication of colorectal cancer screening colonoscopy by treating physician
Exclusion
- First-degree family history of CRC
- Inflammatory bowel disease (ulcerative colitis, Crohn's disease)
- Other malignancies within 5 years
- Known hereditary CRC syndromes (Lynch, FAP)
- Major trauma, surgery, transfusion in past 30 days
- Current participation in an interventional clinical trial
Key Trial Info
Start Date :
April 4 2024
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 1 2028
Estimated Enrollment :
3200 Patients enrolled
Trial Details
Trial ID
NCT07168876
Start Date
April 4 2024
End Date
December 1 2028
Last Update
September 11 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Epiliquid
Mendoza, Mendoza Province, Argentina, 5500